Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
ALLG MM26/D1/AMN009 Novel Combinations for Orphan Myeloma (NORM) Platform Study
Georgia McCaughan, BMedSc,MBBS,MMed,FRACP,FRCPA
Staff Specialist Haematologist
Department of Hematology, St. Vincent’s Hospital
Darlinghurst, New South Wales, Australia